More Access and Evidence Articles

Access and Evidence

Face Value

Danielle Barron, (Feb 21, 2017)

With oncology drug prices under intense and growing scrutiny, how are companies proving the value of their medicines?
Access and Evidence

Strength in Numbers

Danielle Barron, (Feb 20, 2017)

R&D innovation is being accelerated through the nurturing of a ground breaking public-private relationship
Access and Evidence

Access All Areas

Deirdre Coleman, (Feb 15, 2017)

Numerous barriers impede the full realization of benefit from Real World Evidence
Access and Evidence

The Price of Everything and the Value of Nothing

Hugh Gosling, (Feb 9, 2017)

What is value and how do we prove it? Economist Dr Jason Shafrin talks prices, politics and the problem of monopolies.
Access and Evidence

Real-World Revolution Part 2

Deirdre Coleman, (Jan 23, 2017)

Changing mindsets in clinical research
Access and Evidence

Real-World Revolution

Deirdre Coleman, (Jan 19, 2017)

Part 1 of a 2 part series: Unlock valuable insights throughout the lifecycle
Access and Evidence

Singing in Harmony

Adam Hill, (Jan 5, 2017)

Will EUnetHTA succeed in harmonizing the value assessment of medicines across the European Union?
Access and Evidence

Adapt or Die: Real-World Evidence Across the Lifecycle

Deirdre Coleman, (Dec 20, 2016)

The regulator’s view of real-world evidence
Access and Evidence

Mind the Gap

Adam Hill, (Dec 13, 2016)

The importance of real-world evidence in market access is growing, but what rules can pharma follow to close the evidence gaps?
Access and Evidence

Access Denied

Adam Hill, (Oct 12, 2016)

Further embedding market access into the organization: We look into talent and organizational considerations.

Pages